Recent Updates
Recently added Catalysts
CHRS

Coherus BioSciences to Report Second Quarter 2021 Financial Results on August 5th

Key Takeaway: REDWOOD CITY, Calif., July 26, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that its second quarter 2021 financial results will be released after market close on Thursday, August 5, 2021. Starting at 5 p.m. ET, Coherus’ management
Price reaction · baseline $13.07 (2021-07-23 close) · clean, no other CHRS news in the window
day 0 close · peak
-1.7%

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+136%
120-day peak, hindsight
Typical move
6.6%
average across 12 past catalysts
Cash runway
~5 mo
High dilution risk
Lead asset
CHS-0214
Phase 3 · Rheumatoid Arthritis

Full Press Release Details

REDWOOD CITY, Calif., July 26, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that its second quarter 2021 financial results will be released after market close on Thursday, August 5, 2021. Starting at 5 p.m. ET, Coherus’ management team will host a conference call and webcast to discuss financial results and provide a general business update.
After releasing second quarter financial results, the Company will post them on the Coherus website at https://investors.coherus.com.
Conference Call Information
When: Thursday, August 5, 2021 starting at 5:00 p.m. ET
Dial-in: (844) 452-6826 (Toll-Free U.S. and Canada) or (765) 507-2587 (International)
Conference ID: 9146617
Please dial-in 15 minutes early to ensure a timely connection to the call.
About Coherus BioSciences
Coherus is a commercial stage biopharmaceutical company with the mission to increase access to cost-effective medicines that can have a major impact on patients’ lives and to deliver significant savings to the health care system. For additional information, please visit www.coherus.com.
Last updated: Jul 26, 2021